Header Logo

Connection

ELIZABETH SHPALL to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Breast Neoplasms.
ELIZABETH SHPALL
Connection Strength
1.112
Breast Neoplasms
  1. High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later? Biol Blood Marrow Transplant. 2012 Jan; 18(1):3-5.
    View in: PubMed
    Score: 0.071
  2. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol. 2009 Mar; 21(2):150-7.
    View in: PubMed
    Score: 0.059
  3. High-dose chemotherapy for breast cancer: is another look warranted? Curr Opin Oncol. 2004 Mar; 16(2):114-9.
    View in: PubMed
    Score: 0.042
  4. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood. 2000 Nov 01; 96(9):3001-7.
    View in: PubMed
    Score: 0.033
  5. High-dose chemotherapy for breast cancer. Cancer Treat Res. 2000; 103:77-114.
    View in: PubMed
    Score: 0.031
  6. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95.
    View in: PubMed
    Score: 0.031
  7. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood. 1999 Jul 01; 94(1):340-7.
    View in: PubMed
    Score: 0.030
  8. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood. 1999 Apr 15; 93(8):2491-501.
    View in: PubMed
    Score: 0.030
  9. Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematol Cell Ther. 1999 Apr; 41(2):82-6.
    View in: PubMed
    Score: 0.030
  10. Peripheral blood stem cell transplantation in breast cancer. Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun; 12(1-2):219-32.
    View in: PubMed
    Score: 0.029
  11. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood. 1997 Dec 01; 90(11):4313-20.
    View in: PubMed
    Score: 0.027
  12. High-dose chemotherapy for the treatment of breast and ovarian cancer. Curr Opin Oncol. 1997 Mar; 9(2):122-5.
    View in: PubMed
    Score: 0.026
  13. Use of amifostine in bone marrow purging. Semin Oncol. 1996 Aug; 23(4 Suppl 8):44-8.
    View in: PubMed
    Score: 0.025
  14. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res. 1995 Dec 01; 55(23 Suppl):5921s-5924s.
    View in: PubMed
    Score: 0.023
  15. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994 Jun 01; 83(11):3132-7.
    View in: PubMed
    Score: 0.021
  16. High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. Curr Opin Oncol. 1994 Mar; 6(2):135-8.
    View in: PubMed
    Score: 0.021
  17. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol. 1994 Jan; 12(1):28-36.
    View in: PubMed
    Score: 0.021
  18. Transplantation of CD34+ hematopoietic progenitor cells. J Hematother. 1994; 3(2):145-7.
    View in: PubMed
    Score: 0.021
  19. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun; 11(6):1132-43.
    View in: PubMed
    Score: 0.020
  20. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. Breast Cancer Res Treat. 1993; 26 Suppl:S19-23.
    View in: PubMed
    Score: 0.019
  21. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Breast Cancer Res Treat. 1993; 26 Suppl:S11-7.
    View in: PubMed
    Score: 0.019
  22. Treatment of breast cancer in the 1990s. What does the future hold? Drugs. 1992 Feb; 43(2):141-5.
    View in: PubMed
    Score: 0.018
  23. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant. 1991 Feb; 7(2):145-51.
    View in: PubMed
    Score: 0.017
  24. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol. 1991 Jan; 9(1):85-93.
    View in: PubMed
    Score: 0.017
  25. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 333:321-35; discussion 336.
    View in: PubMed
    Score: 0.016
  26. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13.
    View in: PubMed
    Score: 0.015
  27. Intensive single-agent mitoxantrone for metastatic breast cancer. J Natl Cancer Inst. 1988 Apr 06; 80(3):204-8.
    View in: PubMed
    Score: 0.014
  28. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol. 2007 Oct 01; 25(28):4405-13.
    View in: PubMed
    Score: 0.013
  29. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer. 2007 Aug 06; 97(3):391-7.
    View in: PubMed
    Score: 0.013
  30. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant. 2006 Feb; 12(2):195-203.
    View in: PubMed
    Score: 0.012
  31. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15; 104(8):1580-9.
    View in: PubMed
    Score: 0.012
  32. Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. Am J Clin Oncol. 2005 Jun; 28(3):248-54.
    View in: PubMed
    Score: 0.011
  33. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200.
    View in: PubMed
    Score: 0.011
  34. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant. 2004 Nov; 10(11):794-804.
    View in: PubMed
    Score: 0.011
  35. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res. 2004 Nov 01; 10(21):7136-43.
    View in: PubMed
    Score: 0.011
  36. Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol. 2004 Nov; 26(1-2):31-56.
    View in: PubMed
    Score: 0.011
  37. Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier. J Clin Oncol. 2004 Oct 01; 22(19):3846-7.
    View in: PubMed
    Score: 0.011
  38. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res. 2004 Aug 01; 10(15):5076-86.
    View in: PubMed
    Score: 0.011
  39. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant. 2004 Jun; 10(6):415-25.
    View in: PubMed
    Score: 0.011
  40. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res. 2004 Apr 15; 10(8):2609-17.
    View in: PubMed
    Score: 0.010
  41. Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003 Aug 01; 168(3):318-22.
    View in: PubMed
    Score: 0.010
  42. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):707-18.
    View in: PubMed
    Score: 0.009
  43. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002; 8(7):368-76.
    View in: PubMed
    Score: 0.009
  44. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 2000 May; 18(10):2070-80.
    View in: PubMed
    Score: 0.008
  45. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. Blood. 2000 Mar 15; 95(6):2169-74.
    View in: PubMed
    Score: 0.008
  46. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant. 2000; 6(2A):198-203.
    View in: PubMed
    Score: 0.008
  47. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res. 1999 Nov; 5(11):3425-31.
    View in: PubMed
    Score: 0.008
  48. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol. 1999 Oct; 17(10):3064-74.
    View in: PubMed
    Score: 0.008
  49. Autologous stem-cell transplantation for solid tumors in adults. Hematol Oncol Clin North Am. 1999 Oct; 13(5):939-68, vi.
    View in: PubMed
    Score: 0.008
  50. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. Bone Marrow Transplant. 1999 Sep; 24(5):491-5.
    View in: PubMed
    Score: 0.008
  51. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res. 1999 Jul; 5(7):1731-7.
    View in: PubMed
    Score: 0.008
  52. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant. 1999 May; 23 Suppl 2:S13-9.
    View in: PubMed
    Score: 0.007
  53. Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. Exp Hematol. 1999 Apr; 27(4):615-23.
    View in: PubMed
    Score: 0.007
  54. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998 May; 16(5):1661-8.
    View in: PubMed
    Score: 0.007
  55. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154.
    View in: PubMed
    Score: 0.007
  56. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant. 1997 Dec; 20(11):931-7.
    View in: PubMed
    Score: 0.007
  57. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997 Oct 15; 90(8):2939-51.
    View in: PubMed
    Score: 0.007
  58. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. Exp Hematol. 1997 Oct; 25(11):1125-39.
    View in: PubMed
    Score: 0.007
  59. Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. Semin Oncol. 1996 Dec; 23(6 Suppl 15):43-8.
    View in: PubMed
    Score: 0.006
  60. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int. 1996 Sep; 50(3):1026-31.
    View in: PubMed
    Score: 0.006
  61. High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results. Bone Marrow Transplant. 1996 Sep; 18 Suppl 1:S26-9.
    View in: PubMed
    Score: 0.006
  62. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol. 1996 May; 14(5):1463-72.
    View in: PubMed
    Score: 0.006
  63. Bone marrow metastases. Hematol Oncol Clin North Am. 1996 Apr; 10(2):321-43.
    View in: PubMed
    Score: 0.006
  64. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Semin Oncol. 1996 Feb; 23(1 Suppl 2):60-7.
    View in: PubMed
    Score: 0.006
  65. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 1996; 41(1):1-13.
    View in: PubMed
    Score: 0.006
  66. Bone marrow involvement by lobular carcinoma of the breast cannot be identified reliably by routine histological examination alone. Hum Pathol. 1994 Aug; 25(8):781-8.
    View in: PubMed
    Score: 0.005
  67. Comparative assays of megakaryocyte progenitors in CD34+ peripheral blood progenitor cell fractions. Prog Clin Biol Res. 1994; 389:415-20.
    View in: PubMed
    Score: 0.005
  68. Positive selection of CD34+ hematopoietic progenitor cells for transplantation. Stem Cells. 1993 Oct; 11 Suppl 3:48-9.
    View in: PubMed
    Score: 0.005
  69. Bone metastases from breast cancer: value of CT bone windows. J Comput Assist Tomogr. 1992 Jul-Aug; 16(4):608-14.
    View in: PubMed
    Score: 0.005
  70. Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res. 1992; 377:637-42.
    View in: PubMed
    Score: 0.004
  71. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer. 1991 Sep 15; 68(6):1272-8.
    View in: PubMed
    Score: 0.004
  72. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990 Aug 01; 66(3):431-6.
    View in: PubMed
    Score: 0.004
  73. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol. 1990 Jul; 94(1):8-13.
    View in: PubMed
    Score: 0.004
  74. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res. 1989 Aug 15; 49(16):4659-64.
    View in: PubMed
    Score: 0.004
  75. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep; 6(9):1368-76.
    View in: PubMed
    Score: 0.004
  76. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006 Apr 15; 107(8):3074-80.
    View in: PubMed
    Score: 0.003
  77. Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. Bone Marrow Transplant. 1999 Jun; 23(12):1323-4.
    View in: PubMed
    Score: 0.002
  78. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. Clin Cancer Res. 1999 Apr; 5(4):747-51.
    View in: PubMed
    Score: 0.002
  79. Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care. 1998; 14(3):419-30.
    View in: PubMed
    Score: 0.002
  80. Comparison of retroviral-mediated gene transfer into cultured human CD34+ hematopoietic progenitor cells derived from peripheral blood, bone marrow, and fetal umbilical cord blood. Biol Blood Marrow Transplant. 1997 Nov; 3(5):273-81.
    View in: PubMed
    Score: 0.002
  81. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst. 1993 Apr 21; 85(8):640-7.
    View in: PubMed
    Score: 0.001
  82. Myocardial ischemia associated with high-dose carmustine infusion. Cancer. 1991 Nov 01; 68(9):1910-2.
    View in: PubMed
    Score: 0.001
  83. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 338:121-8.
    View in: PubMed
    Score: 0.001
  84. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol. 1989; 23(6):377-83.
    View in: PubMed
    Score: 0.001
  85. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 07; 318(14):869-76.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.